Stock Events

Stock Events

Enanta Pharmaceuticals 

€12.2
0
+€0.1+0.83% Today

Statistics

Day High
12.3
Day Low
12.2
52W High
14
52W Low
4.38
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q4 2025
Next
-0.64
-0.55
-0.45
-0.35
Expected EPS
-0.41588852243
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9EP.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a direct competitor in the antiviral drug market, particularly in treatments for hepatitis C, where Enanta and Gilead have had collaborations but also compete.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes with Enanta in the hepatitis C virus (HCV) treatment market, especially since Enanta has developed drugs that are part of AbbVie's HCV treatment regimens.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is involved in developing treatments for infectious diseases, including hepatitis C, directly competing with Enanta's drug development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals competes with Enanta in the development of treatments for cystic fibrosis, as both companies are involved in creating therapies for genetic and chronic diseases.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in the antiviral space, particularly in hepatitis B and C, areas where Enanta Pharmaceuticals has significant interest and development efforts.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes across a broad range of therapeutic areas, including antiviral drugs, which puts it in competition with Enanta Pharmaceuticals in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Enanta in the development of treatments for infectious diseases, including hepatitis C.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline competes with Enanta in the development of vaccines and treatments for viral infections, including hepatitis and respiratory diseases.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.48B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics for chronic diseases, including hepatitis B, making it a competitor in the viral infection treatment market.

About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Dr. Jay R. Luly Ph.D.
Employees
120
Country
United States
ISIN
US29251M1062

Listings

STU
DE
9EP.STU
MU
DE
9EP.MU
F
DE
9EP.F
XNAS
US
ENTA

0 Comments

Share your thoughts

FAQ

What is Enanta Pharmaceuticals stock price today?▼
The current price of 9EP.STU is €12.2 EUR — it has increased by +0.83% in the past 24 hours. Watch Enanta Pharmaceuticals stock price performance more closely on the chart.
What is Enanta Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enanta Pharmaceuticals stocks are traded under the ticker 9EP.STU.
Is Enanta Pharmaceuticals stock price growing?▼
9EP.STU stock has risen by +4.27% compared to the previous week, the month change is a +7.96% rise, over the last year Enanta Pharmaceuticals has showed a +176.02% increase.
When is the next Enanta Pharmaceuticals earnings date?▼
Enanta Pharmaceuticals is going to release the next earnings report on May 11, 2026.
What were Enanta Pharmaceuticals earnings last quarter?▼
9EP.STU earnings for the last quarter are -0.35 EUR per share, whereas the estimation was -0.64 EUR resulting in a +45.29% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Enanta Pharmaceuticals have?▼
As of May 06, 2026, the company has 120 employees.
In which sector is Enanta Pharmaceuticals located?▼
Enanta Pharmaceuticals operates in the Health & Wellness sector.
When did Enanta Pharmaceuticals complete a stock split?▼
Enanta Pharmaceuticals has not had any recent stock splits.
Where is Enanta Pharmaceuticals headquartered?▼
Enanta Pharmaceuticals is headquartered in Watertown, United States.